Mon panier

Cynomolgus LILRB4 / CD85k / ILT3 Protein, His Tag (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CDK-C5227-100ug
$465.00
CDK-C5227-1mg (500ug X 2)
$3170.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    LILRB4, ILT3, LIR5, CD85K, HM18

  • Source

    Cynomolgus LILRB4, His Tag (CDK-C5227) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Glu 259 (Accession # XP_015297198.1).

    Predicted N-terminus: Gln 22

    Request for sequence
  • Molecular Characterization

    LILRB4 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 28.0 kDa. The protein migrates as 34-42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    LILRB4 SDS-PAGE

    Cynomolgus LILRB4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    LILRB4 SEC-MALS

    The purity of Cynomolgus LILRB4, His Tag (Cat. No. CDK-C5227) is more than 85% and the molecular weight of this protein is around 30-42 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LILRB4 ELISA

    Immobilized Cynomolgus LILRB4, His Tag (Cat. No. CDK-C5227) at 2 μg/mL (100 μL/well) can bind Human ANGPTL7, His Tag with a linear range of 8-125 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     LILRB4 SPR

    Cynomolgus LILRB4, His Tag (Cat. No. CDK-C5227) immobilized on CM5 Chip can bind Human ANGPTL7 Protein, His Tag (Cat. No. AN7-H52H3) with an affinity constant of 0.792 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Leukocyte immunoglobulin-like receptor subfamily B member 4

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    7 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte